GB201710835D0 - ROR1 Antibodies - Google Patents

ROR1 Antibodies

Info

Publication number
GB201710835D0
GB201710835D0 GBGB1710835.8A GB201710835A GB201710835D0 GB 201710835 D0 GB201710835 D0 GB 201710835D0 GB 201710835 A GB201710835 A GB 201710835A GB 201710835 D0 GB201710835 D0 GB 201710835D0
Authority
GB
United Kingdom
Prior art keywords
ror1 antibodies
ror1
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1710835.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB1710835.8A priority Critical patent/GB201710835D0/en
Publication of GB201710835D0 publication Critical patent/GB201710835D0/en
Priority to AU2018297630A priority patent/AU2018297630B2/en
Priority to CA3068196A priority patent/CA3068196A1/en
Priority to PCT/GB2018/051914 priority patent/WO2019008377A1/en
Priority to MX2019015348A priority patent/MX2019015348A/es
Priority to CN201880045361.4A priority patent/CN110891973B/zh
Priority to DK18742575.6T priority patent/DK3649152T3/da
Priority to JP2019572456A priority patent/JP7242573B2/ja
Priority to US16/628,512 priority patent/US11466083B2/en
Priority to ES18742575T priority patent/ES3048696T3/es
Priority to EP18742575.6A priority patent/EP3649152B1/en
Priority to US17/869,872 priority patent/US20230220073A1/en
Priority to US18/815,603 priority patent/US20250066472A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
GBGB1710835.8A 2017-07-05 2017-07-05 ROR1 Antibodies Ceased GB201710835D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1710835.8A GB201710835D0 (en) 2017-07-05 2017-07-05 ROR1 Antibodies
EP18742575.6A EP3649152B1 (en) 2017-07-05 2018-07-05 Ror1 antibodies
DK18742575.6T DK3649152T3 (da) 2017-07-05 2018-07-05 ROR1-antistoffer
CA3068196A CA3068196A1 (en) 2017-07-05 2018-07-05 Ror1 antibodies
PCT/GB2018/051914 WO2019008377A1 (en) 2017-07-05 2018-07-05 ANTIBODY ROR1
MX2019015348A MX2019015348A (es) 2017-07-05 2018-07-05 Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).
CN201880045361.4A CN110891973B (zh) 2017-07-05 2018-07-05 Ror1抗体
AU2018297630A AU2018297630B2 (en) 2017-07-05 2018-07-05 ROR1 antibodies
JP2019572456A JP7242573B2 (ja) 2017-07-05 2018-07-05 Ｒｏｒ１抗体
US16/628,512 US11466083B2 (en) 2017-07-05 2018-07-05 ROR1 antibodies
ES18742575T ES3048696T3 (en) 2017-07-05 2018-07-05 Ror1 antibodies
US17/869,872 US20230220073A1 (en) 2017-07-05 2022-07-21 Ror1 antibodies
US18/815,603 US20250066472A1 (en) 2017-07-05 2024-08-26 Ror1 antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1710835.8A GB201710835D0 (en) 2017-07-05 2017-07-05 ROR1 Antibodies

Publications (1)

Publication Number Publication Date
GB201710835D0 true GB201710835D0 (en) 2017-08-16

Family

ID=59592560

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1710835.8A Ceased GB201710835D0 (en) 2017-07-05 2017-07-05 ROR1 Antibodies

Country Status (11)

Country Link
US (3) US11466083B2 (https=)
EP (1) EP3649152B1 (https=)
JP (1) JP7242573B2 (https=)
CN (1) CN110891973B (https=)
AU (1) AU2018297630B2 (https=)
CA (1) CA3068196A1 (https=)
DK (1) DK3649152T3 (https=)
ES (1) ES3048696T3 (https=)
GB (1) GB201710835D0 (https=)
MX (1) MX2019015348A (https=)
WO (1) WO2019008377A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2022040506A2 (en) * 2020-08-21 2022-02-24 Yale University Nanobody compositions and methods of use of the same
EP4200336A4 (en) * 2020-08-24 2024-09-25 Epimab Biotherapeutics (HK) Limited Anti-ror1 antibodies and related bispecific binding proteins
EP4209509A4 (en) * 2020-09-03 2025-03-19 Harbour Biomed (Shanghai) Co., Ltd ROR1-TARGETTING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION THEREOF AND USE THEREOF
WO2022109403A1 (en) * 2020-11-23 2022-05-27 Scout Bio, Inc. Antigen-binding molecules and uses thereof
WO2022182562A1 (en) * 2021-02-23 2022-09-01 BioLegend, Inc. ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
US20240309116A1 (en) * 2021-07-23 2024-09-19 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against ror1 and uses thereof
CN113956359B (zh) * 2021-10-29 2022-09-16 叶鑫淼 一种抗体及其在抗肿瘤中的应用
KR20240125944A (ko) * 2021-12-28 2024-08-20 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-ror1 항체 및 항-ror1 항체 약물 접합체 및 이의 의약적 용도
TW202413422A (zh) * 2022-07-11 2024-04-01 美商翰森生物有限責任公司 抗體、其抗原結合片段及其藥物用途
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
CN118440200B (zh) * 2023-04-21 2025-05-16 星奕昂(上海)生物科技有限公司 靶向ror1的抗体及其应用
AU2024331841A1 (en) * 2023-08-31 2026-03-05 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
CA2759733C (en) * 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
WO2011054007A1 (en) * 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
ES2657970T3 (es) 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos contra ROR1 de conejo/ser humano quiméricos
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
ES2702315T3 (es) * 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
WO2016016344A1 (en) * 2014-07-29 2016-02-04 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
US10544201B2 (en) 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
WO2016039321A1 (ja) 2014-09-08 2016-03-17 国立研究開発法人国立がん研究センター がん細胞特異的な抗体、抗がん剤、及びがんの検査方法
CA2963696A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
ES2818103T3 (es) 2015-01-16 2021-04-09 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos para ROR1
CN107567445B (zh) 2015-02-02 2021-06-29 坎塞拉有限公司 可用作哺乳动物酪氨酸激酶ror1活性抑制剂的2-苯基-3h-咪唑并[4,5-b]吡啶衍生物
WO2016187216A1 (en) 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
TW201734049A (zh) 2016-01-22 2017-10-01 健生生物科技公司 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
EP3481824B1 (en) 2016-07-11 2021-10-20 Kancera AB 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
US20200338210A1 (en) 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
JP2020521448A (ja) 2017-05-23 2020-07-27 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、およびｒｏｒ１またはｒｏｒ２に結合するタンパク質
AU2018289581C1 (en) 2017-06-23 2025-01-30 VelosBio Inc. ROR1 antibody immunoconjugates
US11987635B2 (en) 2017-06-25 2024-05-21 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Anti-4-1BB antibodies and methods of making and using thereof
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
US20210139579A1 (en) 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
EP3703711A4 (en) 2017-11-03 2021-01-13 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-MMR1 IMMUNOTHERAPY
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도

Also Published As

Publication number Publication date
CN110891973A (zh) 2020-03-17
MX2019015348A (es) 2020-07-20
AU2018297630B2 (en) 2025-03-06
JP2020530272A (ja) 2020-10-22
EP3649152B1 (en) 2025-10-08
CA3068196A1 (en) 2019-01-10
JP7242573B2 (ja) 2023-03-20
EP3649152A1 (en) 2020-05-13
WO2019008377A1 (en) 2019-01-10
DK3649152T3 (da) 2025-11-10
US11466083B2 (en) 2022-10-11
ES3048696T3 (en) 2025-12-11
US20230220073A1 (en) 2023-07-13
AU2018297630A1 (en) 2020-01-16
US20250066472A1 (en) 2025-02-27
US20200354448A1 (en) 2020-11-12
CN110891973B (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
ZA201905966B (en) Anti-lag3 antibodies
IL268517A (en) Anti-tigit antibodies
SG11202000660QA (en) Anti-tigit antibodies
ZA202002141B (en) Anti-transthyretin antibodies
HUE067040T2 (hu) Anti-SIRPalfa antitestek
GB201709808D0 (en) Antibodies
GB201710835D0 (en) ROR1 Antibodies
GB201601073D0 (en) Antibodies
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
GB201610044D0 (en) Antibodies
ZA202103456B (en) Anti-alpha-synuclein antibodies
GB201720970D0 (en) Antibodies
GB201603291D0 (en) Antibodies
IL273529A (en) Anti-PACAP antibody
IL271067A (en) Anti-trkb antibodies
GB201612337D0 (en) Ant-il-22r antibodies
PT3456736T (pt) Variantes de anticorpos
ZA202001830B (en) Antibody variants
IL272951A (en) antibody variants
GB201711785D0 (en) Antibodies
HK40017256A (en) Ror1 antibodies
GB201717006D0 (en) Anti-OPG antibodies
GB201709818D0 (en) Antibodies
GB201709592D0 (en) Antibody
GB201703071D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)